Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07397338 · ClinicalTrials.gov registry record · Phase 1
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Phase 1 study of Advanced Solid Tumors and NSCLC, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 370
- Enrollment target
- 1
- Study location
NCT07397338: Recruiting Phase 1 study of Advanced Solid Tumors and NSCLC, sponsored by Revolution Medicines.
NCT07397338 is a Phase 1 study of Advanced Solid Tumors and NSCLC that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 370 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (89% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07397338, a Phase 1 study of Advanced Solid Tumors and NSCLC, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 370 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Primary Outcome
Number of patients with AEs as assessed by CTCAE v5.
Conditions Studied
Interventions
- DRUG Ivonescimab
- DRUG Elironrasib
- DRUG Daraxonrasib
- DRUG Zoldonrasib
- DRUG Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)
Study Locations (1)
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
What NCT07397338 shows while recruiting
NCT07397338 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (89% higher).
The record links to 6 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Ivonescimab is the first listed.
NCT07397338 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT07397338 about?
NCT07397338 is a clinical study titled "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
What is the current status of trial NCT07397338?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 370 participants. The study started on 2026-01-30. Estimated completion is 2029-05.
What conditions does trial NCT07397338 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, NSCLC, Non-small Cell Lung Cancer (NSCLC), Metastatic Solid Tumors, Colorectal Cancer (CRC).
What interventions are being tested in trial NCT07397338?
The interventions under investigation include: Ivonescimab (DRUG), Elironrasib (DRUG), Daraxonrasib (DRUG), Zoldonrasib (DRUG), Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) (DRUG).
Who is sponsoring clinical trial NCT07397338?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07397338 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07397338's enrollment target sits among peer trials
370 16th of 144 higher than 129 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI